MAPT and early-onset autosomal dominant Alzheimer disease: Applied to 1,891 participants from the Alzheimer’s Disease Neuroimaging Initiative, the model accurately predicts key AD biomarkers—including amyloid-β, tau, neurodegeneration, and cognition—outperforming clinical and neuroimaging benchmarks.